

VIAL LADEL DIMENSIONS COMMIS		(H) 60 X (L) 33		
PACK SIZE	100 mL		COLORS	
DIMENSIONS (MM)	(H) 140 x	(L) 50 x (W) 40		ReflexBlueC

10 mg/mL (1 g/100 mL)

1235 C

DOSAGE STR

APPROVED BY: DATE: SIGNATURE: REVISION NUMBER:

Solution for IV Infusion

PARAM

BRAND NAME

DOSAGE FORM

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.



10 mg/mL (1 g/100 mL) Solution for IV Infusion Analgesic & Antipyretic

Formulation:

Each mL contains:

Paracetamol BP....

Indications

Paracetamol is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics, and for reduction of fever.

Dosage and Administration

The Paracetamol solution is administered as a 15-minute intravenous infusion.

Adolescents and adults weighing more than 50 kg:

Paracetamol 1 g per administration, up to four times a day or 650 mg every 4 hours to a maximum of 4 g per day period minimum dosing interval of

Children, adolescents and adults weighing less than 50 kg:

Paracetamol 15 mg/kg per administration, i.e. 1.5 mL solution per kg up to four times a day or 12.5 mg/kg every 4 hours to a maximum of 75 mg/kg per day. The minimum interval between each administration must be 4 hours.

"Severe renal insufficiency": it is recommended, when giving Paracetamol to patients with severe renal impairment (creatinine clearance 30 mL/min), to increase the minimum interval between each administration to 6 hours.

"In adults with hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione) and dehydration, the maximum daily dose must not exceed 3 g"

Contraindications

Paracetamol is contraindicated:

- in patients with hypersensitivity to Paracetamol or to proparacetamol hydrochloride (prodrug of paracetamol) or to any of the excipients
- in cases of severe hepatic impairment or severe active liver disease.

Warnings and Precautions

Doses higher than those recommended entail the risk of very serious liver damage hepatic injury, including the rise of liver failure and death. Clinical signs and symptoms of liver damage (including fulminant hepatitis, hepatic failure, cholestatic hepatitis, cytolytic hepatitis) are usually first seen after two days of drug administration with a peak seen, usually after 4-6 days. Treatment with antidote should be given as soon as possible.

Paracetamol should only be used during pregnancy after a careful benefit-risk assessment. In this case, the recommended posology and duration must be strictly observed.

After oral administration, paracetamol is excreted into breast milk in small quantities. No undesirable effects on nursing infants have been reported. Consequently, paracetamol may be used in breast-feeding women.

Drug interaction:

Probenecid causes an almost 2-fold reduction in clearance of paracetamol by inhibiting its conjugation with glucuronic acid. A reduction in the paracetamol dose should be considered if it is to be used concomitantly with probenecid. Salicylamide may prolong the elimination t\(\frac{1}{2} \) of paracetamol.

Caution should be taken with the concomitant intake of enzyme-inducing substances.

Serious adverse effects:

·Hepatic injury

·Serious skin reactions

- -Acute generalised exanthematous pustulosis (AGEP)
- -Stevens-Johnson Syndrome (SJS)
- -Toxic epidermal necrolysis (TEN)

·Allergy and hypersensitivity

-Swelling of the face, mouth and throat, respiratory distress, urticaria, rash, and pruritis.

Most common adverse effects:

Gastrointestinal disorder: Nausea, Vomiting General disorders and administration site conditions: Pyrexia Nervous system disorders: Headache Psychiatric: Insomnia

Other adverse effects in Adults:

Blood Lymphatic system disorders: anemia

General disorders and administration site conditions: fatigue, infusion site pain, peripheral edema

Investigations: Aspartate aminotransferase increases breath sounds abnorma

Metabolism and Nutrition disorders: Hypokalemia

Musculoskeletal and connective tissue disorders: muscle spasms, tissues

Psychiatric disorders: anxiety

Respiratory, thoracic and mediastinal disorders: dyspnea

Vascular disorders: hypertension, hypotension

Other adverse effects in pediatrics:

Blood and lymphatics system disorders: anemia

Cardiac disorders: tachycardia

Gastrointestinal disorder: abdominal pain, diarrhea

General disorders and administration site conditions: injection site pain, peripheral edema, pyrexia

Investigations: hepatic enzyme increase

Metabolism and Nutrition disorders: hypoalbuminemia, hypokalemia, hypomagnesemia, hypophosphatemia, hyporvolemia

Musculoskeletal and connective tissue disorders: muscle spasm, pain in extremity

Nervous system disorders: Headache

Psychiatric distress: Insomnia

Renal and urinary disorders: oliguria

Respiratory, thoracic and mediastinal disorders: pulmonary edema, hypoxia, pleural effusion, stridor, wheezing

Skin and subcutaneous tissue disorders: periorbital edema, rash

Vascular disorders: hypertension, hypotension.

Availability: Form Fill Seal LDPE bottle of 100 mL packed in a carton.

Storage: Store at temperatures not exceeding 30°C. Protect from light.

KEEP ALL MEDICINES OUT OF REACH OF CHILDREN.

Caution: Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.



Imported & Distributed by **BIOCARE LIFESCIENCES INC.** 4th Floor, 393 Goodwill Bldg., Senator Gil Puyat Avenue, Brgy. Bel-Air, Makati City

Manufactured by: AMN Life Science Pvt. Ltd. 150, Sahajanand Estate, Sarkhei. Tal. City, Ahmedabad, Gujarat, India.